These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 25643584

  • 21. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model.
    Yin SC, Guo W, Tao ZZ.
    Biochem Biophys Res Commun; 2013 Sep 13; 439(1):1-5. PubMed ID: 23973483
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
    van der Meel R, Oliveira S, Altintas I, Heukers R, Pieters EH, van Bergen en Henegouwen PM, Storm G, Hennink WE, Kok RJ, Schiffelers RM.
    Mol Pharm; 2013 Oct 07; 10(10):3717-27. PubMed ID: 23889133
    [Abstract] [Full Text] [Related]

  • 23. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
    Cancer Res; 2001 Sep 15; 61(18):6747-54. PubMed ID: 11559546
    [Abstract] [Full Text] [Related]

  • 24. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
    Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D.
    Endocr Relat Cancer; 2009 Jun 15; 16(2):429-41. PubMed ID: 19153208
    [Abstract] [Full Text] [Related]

  • 25. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
    Liu KJ, Chen CT, Hu WS, Hung YM, Hsu CY, Chuang BF, Juang SH.
    Int J Oncol; 2004 Mar 15; 24(3):581-90. PubMed ID: 14767543
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L, Wang Y, Wang H, Gao H, Liang J, Sui A, Xiang J, Zhou F, Xu C, Zhao W, Liang W, Yao R.
    Oncol Rep; 2012 Oct 15; 28(4):1453-60. PubMed ID: 22895605
    [Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C.
    Cancer Res; 2006 Jan 01; 66(1):362-71. PubMed ID: 16397250
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV.
    Oncogene; 2004 Jul 01; 23(30):5161-74. PubMed ID: 15122317
    [Abstract] [Full Text] [Related]

  • 29. CHM-1 Suppresses Formation of Cell Surface-associated GRP78-p85α Complexes, Inhibiting PI3K-AKT Signaling and Inducing Apoptosis of Human Nasopharyngeal Carcinoma Cells.
    Lin ML, Chen SS, Ng SH.
    Anticancer Res; 2015 Oct 01; 35(10):5359-68. PubMed ID: 26408697
    [Abstract] [Full Text] [Related]

  • 30. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K, Kijowski J, Sekuła M, Majka M.
    Oncol Rep; 2012 Nov 01; 28(5):1903-9. PubMed ID: 22941268
    [Abstract] [Full Text] [Related]

  • 31. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
    Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ.
    Mol Cancer Ther; 2012 Mar 01; 11(3):649-59. PubMed ID: 22188815
    [Abstract] [Full Text] [Related]

  • 32. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.
    Arch Biochem Biophys; 2012 Oct 15; 526(2):206-18. PubMed ID: 22464987
    [Abstract] [Full Text] [Related]

  • 33. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
    Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG, Trudel S.
    Clin Cancer Res; 2011 Jul 15; 17(14):4693-704. PubMed ID: 21632854
    [Abstract] [Full Text] [Related]

  • 34. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
    Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC.
    Toxicol Appl Pharmacol; 2013 Nov 01; 272(3):637-46. PubMed ID: 23933164
    [Abstract] [Full Text] [Related]

  • 35. The quinolone derivative CHM-1 inhibits murine WEHI-3 leukemia in BALB/c mice in vivo.
    Lai TY, Yang JS, Wu PP, Huang WW, Kuo SC, Ma CY, Gibson Wood W, Chung JG.
    Leuk Lymphoma; 2010 Nov 01; 51(11):2098-102. PubMed ID: 20846096
    [Abstract] [Full Text] [Related]

  • 36. Activation of insulin-like growth factor type-1 receptor is required for H2O2-induced PKB phosphorylation in vascular smooth muscle cells.
    Azar ZM, Mehdi MZ, Srivastava AK.
    Can J Physiol Pharmacol; 2006 Jul 01; 84(7):777-86. PubMed ID: 16998541
    [Abstract] [Full Text] [Related]

  • 37. Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.
    Chen Y, Niu J, Li L, Li Z, Jiang J, Zhu M, Dong T, Zhang J, Shi C, Xu P, Lu Y, Jiang Y, Liu P, Chen W.
    Life Sci; 2020 Oct 01; 258():118158. PubMed ID: 32750435
    [Abstract] [Full Text] [Related]

  • 38. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.
    Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.
    Cell Commun Signal; 2018 Sep 19; 16(1):61. PubMed ID: 30231881
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.
    Zamykal M, Martens T, Matschke J, Günther HS, Kathagen A, Schulte A, Peters R, Westphal M, Lamszus K.
    Neuro Oncol; 2015 Aug 19; 17(8):1076-85. PubMed ID: 25543125
    [Abstract] [Full Text] [Related]

  • 40. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
    Watanabe T, Ohtani T, Aihara M, Ishiuchi S.
    J Neurosurg; 2013 Apr 19; 118(4):838-45. PubMed ID: 23311938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.